204 related articles for article (PubMed ID: 15229776)
61. I-131-Lipiodol therapy in liver neoplasms.
Risse JH; Grünwald F; Strunk H; Kleinschmidt R; Bender H; Biersack HJ
Hybridoma; 1999 Feb; 18(1):83-5. PubMed ID: 10211793
[TBL] [Abstract][Full Text] [Related]
62. Management of postsurgical recurrence of hepatocellular carcinoma with rhenium 188-HDD labeled iodized oil.
Kumar A; Srivastava DN; Bal C
J Vasc Interv Radiol; 2006 Jan; 17(1):157-61. PubMed ID: 16415146
[TBL] [Abstract][Full Text] [Related]
63. Effects of iodinated fatty acid ester on human hepatocellular carcinoma cells.
Kim H; Park C; Lee YB; Yoo HS; Park JH; Lee WY
Yonsei Med J; 1991 Mar; 32(1):16-23. PubMed ID: 1652177
[TBL] [Abstract][Full Text] [Related]
64. Delayed cerebral lipiodol embolism after transcatheter arterial chemoembolization of hepatocellular carcinoma.
Wu JJ; Chao M; Zhang GQ; Li B
Chin Med J (Engl); 2009 Apr; 122(7):878-80. PubMed ID: 19493407
[No Abstract] [Full Text] [Related]
65. Suitable blending method of lipiodol-cisplatin in transcatheter arterial embolization for hepatocellular carcinoma: evaluation of sustained release and accumulation nature.
Takaki Y; Kaminou T; Shabana M; Ihaya T; Otsubo K; Ogawa T
Hepatogastroenterology; 2008; 55(81):202-6. PubMed ID: 18507107
[TBL] [Abstract][Full Text] [Related]
66. 1,25-Dihydroxyvitamin D3 in lipiodol for the treatment of hepatocellular carcinoma: cellular, animal and clinical studies.
Pourgholami MH; Morris DL
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):513-8. PubMed ID: 15225830
[TBL] [Abstract][Full Text] [Related]
67. Adjuvant treatments for resectable hepatocellular carcinoma.
Ishii H; Yamamoto J; Ikari T
J Hepatobiliary Pancreat Surg; 2008; 15(5):459-62. PubMed ID: 18836796
[TBL] [Abstract][Full Text] [Related]
68. Guidelines for 131I-ethiodised oil (Lipiodol) therapy.
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):BP20-2. PubMed ID: 12723561
[No Abstract] [Full Text] [Related]
69. Case report: localization of lipiodol-radioiodine in hepatic metastases from renal cell carcinoma.
Stansby G; Bhattacharya S; Hilson AJ; Lane DM; Hobbs KE
Br J Radiol; 1994 Aug; 67(800):822-4. PubMed ID: 8087492
[TBL] [Abstract][Full Text] [Related]
70. Eradication of hepatocellular carcinoma xenografts by radiolabelled, lipiodol-inducible gene therapy.
Kawashita Y; Ohtsuru A; Miki F; Kuroda H; Morishita M; Kaneda Y; Hatsushiba K; Kanematsu T; Yamashita S
Gene Ther; 2005 Nov; 12(22):1633-9. PubMed ID: 16079887
[TBL] [Abstract][Full Text] [Related]
71. Interventional nuclear medicine in hepatocellular carcinoma and other tumours.
Buscombe JR
Nucl Med Commun; 2002 Sep; 23(9):837-41. PubMed ID: 12195086
[TBL] [Abstract][Full Text] [Related]
72. Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma.
Li M; Lu C; Cheng J; Zhang J; Cao C; Xu J; Xu J; Pan H; Zhong B; Tucker S; Wang D
J Gastroenterol Hepatol; 2009 Aug; 24(8):1437-44. PubMed ID: 19486255
[TBL] [Abstract][Full Text] [Related]
73. Systemic chemotherapy of hepatocellular carcinoma--Korean experience.
Lee HC
Oncology; 2008; 75 Suppl 1():114-8. PubMed ID: 19092280
[TBL] [Abstract][Full Text] [Related]
74. Patient dosimetry for 131I-lipiodol therapy.
Monsieurs MA; Bacher K; Brans B; Vral A; De Ridder L; Dierckx RA; Thierens HM
Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):554-61. PubMed ID: 12690415
[TBL] [Abstract][Full Text] [Related]
75. Selective effects of Lipiodolized antitumor agents.
Kanematsu T; Inokuchi K; Sugimachi K; Furuta T; Sonoda T; Tamura S; Hasuo K
J Surg Oncol; 1984 Mar; 25(3):218-26. PubMed ID: 6199624
[TBL] [Abstract][Full Text] [Related]
76. 131I lipiodol therapy for unresectable hepatocellular carcinoma.
Rindani RB; Hugh TJ; Roche J; Roach PJ; Smith RC
ANZ J Surg; 2002 Mar; 72(3):210-4. PubMed ID: 12071454
[TBL] [Abstract][Full Text] [Related]
77. Ablation of recurrent primary liver cancer using 131I-lipiodol.
Novell R; Hilson A; Hobbs K
Postgrad Med J; 1991 Apr; 67(786):393-5. PubMed ID: 1648718
[TBL] [Abstract][Full Text] [Related]
78. International Atomic Energy Agency-sponsored multination study of intra-arterial rhenium-188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study.
Bernal P; Raoul JL; Stare J; Sereegotov E; Sundram FX; Kumar A; Jeong JM; Pusuwan P; Divgi C; Zanzonico P; Vidmar G; Buscombe J; Chau TT; Saw MM; Chen S; Ogbac R; Dondi M; Padhy AK
Semin Nucl Med; 2008 Mar; 38(2):S40-5. PubMed ID: 18243842
[TBL] [Abstract][Full Text] [Related]
79. [Selective internal radiotherapy (radioembolization) and radiation therapy for HCC--current status and perspectives].
Hilgard P; Müller S; Hamami M; Sauerwein WS; Haberkorn U; Gerken G; Antoch G
Z Gastroenterol; 2009 Jan; 47(1):37-54. PubMed ID: 19156591
[TBL] [Abstract][Full Text] [Related]
80. Nodular hepatocellular carcinoma--treatment with intraarterial injection of I-131 Lipiodol.
Yoo HS; Suh JH; Lee JT; Kim KW; Kim DI; Kim BS; Choi HJ; Lee KS
J Korean Med Sci; 1990 Jun; 5(2):75-83. PubMed ID: 2177607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
